R
RVMD
Revolution Medicines, Inc.
96.43
+0.21+0.22%After Hours: 97.90 +1.47 +1.52%19:57 04/10 EDT
OPEN/PREV CLOSE97.03/96.22
TODAY RANGE94.63-97.23
VOL1.98M
MARKET CAP19.11B
52 WEEK RANGE29.17-124.49
AVG VOL (3M)2.52M
% TURNOVER1.00%
TURNOVER--
P/E (TTM)-16.2062
% RANGE2.70%
EPS(TTM)-5.9502
P/E(FORWARD)-12.3946
P/B11.65
BVPS8.28
DIVIDEND--
P/S1,687.62
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP18.38B
SHARES OUTSTANDING198.17M
NEXT EARNINGS05/05-05/11
FREE FLOAT190.64M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
Should Launch of Phase 3 RASolute 303 in Metastatic Pancreatic Cancer Require Action From Revolution Medicines (RVMD) Investors?
Seeking Alpha·1d ago
CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
TipRanks·1d ago
Revolution Medicines (RVMD) Gets a Buy from RBC Capital
Simply Wall St·6d ago
A Look At Revolution Medicines (RVMD) Valuation After Starting Pivotal Phase 3 RASolute 303 Trial
Seeking Alpha·04/02 18:29
Tango a new Buy at Canaccord Genuity on 2026 catalysts
TipRanks·04/02 12:24
Revolution Medicines begins treating patients in RASolute 303
TipRanks·04/02 11:00
Revolution Medicines (RVMD) Gets a Buy from Wells Fargo
TipRanks·04/01 11:36
Piper Sandler Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Simply Wall St·04/01 03:24
Is Early RAS(ON) Pancreatic Cancer Data Altering The Investment Case For Revolution Medicines (RVMD)?